Gland Pharma Limited
NSE:GLAND.NS
1764.55 (INR) • At close November 12, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | 2019 Q3 | 2019 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 14,058.33 | 14,017.1 | 15,374.5 | 15,451.55 | 13,734.24 | 12,086.93 | 7,850.11 | 9,382.88 | 10,444.04 | 8,568.98 | 10,864.51 | 10,633.25 | 10,804.69 | 11,539 | 8,485.09 | 8,594.19 | 8,315 | 8,631.84 | 5,737.78 | 6,459.35 | 6,609 |
| Cost of Revenue
| 10,444.74 | 10,582.64 | 11,014.79 | 5,992.39 | 5,215.64 | 4,529.03 | 3,648.41 | 4,270.69 | 5,194.63 | 3,740.54 | 5,452.92 | 5,034.24 | 5,240.08 | 5,364.93 | 3,915.51 | 4,068.68 | 3,735.03 | 3,199.52 | 2,555.49 | 2,774.33 | 2,721.56 |
| Gross Profit
| 3,613.59 | 3,434.46 | 4,359.71 | 9,459.16 | 8,518.6 | 7,557.9 | 4,201.7 | 5,112.19 | 5,249.41 | 4,828.44 | 5,411.59 | 5,599.01 | 5,564.61 | 6,174.07 | 4,569.58 | 4,525.51 | 4,579.97 | 5,432.32 | 3,182.29 | 3,685.02 | 3,887.44 |
| Gross Profit Ratio
| 0.257 | 0.245 | 0.284 | 0.612 | 0.62 | 0.625 | 0.535 | 0.545 | 0.503 | 0.563 | 0.498 | 0.527 | 0.515 | 0.535 | 0.539 | 0.527 | 0.551 | 0.629 | 0.555 | 0.57 | 0.588 |
| Reseach & Development Expenses
| 493 | 489 | 436 | 530 | 351 | 457 | 678 | 512 | 414 | 410 | 559 | 699 | 578 | 438 | 304 | 434 | 0 | 67.62 | 173 | 312 | 52.34 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 29.35 | 0 | 0 | 34.42 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 91.66 | 0 | 0 | 33.67 |
| SG&A
| 1,088.28 | 1,221.11 | 1,263.29 | 1,271.61 | 1,294.47 | 2,550.04 | 516.19 | 401 | 533.28 | 980.01 | 957.06 | 814.32 | 823.18 | 345.23 | 405.7 | 821.67 | 785.58 | 121.01 | 695.79 | 672.12 | 68.09 |
| Other Expenses
| 0 | 514.26 | 421.47 | 373.91 | 531.55 | 375.42 | 389.39 | 615.09 | 656.24 | 743.91 | -1,571.05 | 456.69 | 511.97 | 618.38 | -792.85 | 351.3 | 203.52 | 28.66 | -919.89 | 252.88 | 1.93 |
| Operating Expenses
| 1,581.28 | 1,710.11 | 1,699.29 | 6,948.68 | 6,090.81 | 5,271.51 | 2,892.94 | 2,592.58 | 2,647.62 | 2,478.33 | 2,233.56 | 2,388.23 | 2,059.79 | 2,064.04 | 1,539.32 | 2,132.84 | 1,849.6 | 1,546.93 | 1,008.28 | 1,809.62 | 1,479.28 |
| Operating Income
| 2,032.31 | 1,724.35 | 2,660.42 | 2,884.39 | 2,959.34 | 2,286.39 | 1,133.54 | 3,134.7 | 3,258.03 | 2,350.11 | 3,174.61 | 3,210.78 | 3,504.92 | 4,110.03 | 3,030.26 | 2,392.67 | 2,933.89 | 3,885.39 | 2,174.01 | 1,875.4 | 2,408.16 |
| Operating Income Ratio
| 0.145 | 0.123 | 0.173 | 0.187 | 0.215 | 0.189 | 0.144 | 0.334 | 0.312 | 0.274 | 0.292 | 0.302 | 0.324 | 0.356 | 0.357 | 0.278 | 0.353 | 0.45 | 0.379 | 0.29 | 0.364 |
| Total Other Income Expenses Net
| 535.47 | 458.1 | 321.89 | -52.81 | -60.46 | 326.27 | -22.03 | -26.2 | -17.21 | 734.88 | 630.23 | 444.85 | 501.73 | 608.37 | 459.17 | 339.71 | -7.6 | 314.61 | 441.11 | 196.1 | 335.1 |
| Income Before Tax
| 2,567.78 | 2,182.45 | 2,982.31 | 2,831.58 | 2,898.88 | 2,612.66 | 1,111.51 | 3,108.5 | 3,240.82 | 3,084.99 | 3,804.84 | 3,655.63 | 4,006.65 | 4,718.4 | 3,489.43 | 2,732.38 | 2,926.29 | 4,200 | 2,615.12 | 2,071.5 | 2,743.26 |
| Income Before Tax Ratio
| 0.183 | 0.156 | 0.194 | 0.183 | 0.211 | 0.216 | 0.142 | 0.331 | 0.31 | 0.36 | 0.35 | 0.344 | 0.371 | 0.409 | 0.411 | 0.318 | 0.352 | 0.487 | 0.456 | 0.321 | 0.415 |
| Income Tax Expense
| 932.46 | 744.84 | 1,058.1 | 913.02 | 958.06 | 671.64 | 324.68 | 789.01 | 828.4 | 793.3 | 945.82 | 925.34 | 985.84 | 1,211.88 | 885.34 | 691.31 | 737.72 | 1,064.1 | 667.19 | 530.51 | 905.52 |
| Net Income
| 1,635.32 | 1,437.61 | 1,924.2 | 1,918.56 | 1,940.82 | 1,941.02 | 786.83 | 2,319.49 | 2,412.42 | 2,291.69 | 2,859.02 | 2,730.29 | 3,020.81 | 3,506.52 | 2,604.09 | 2,041.07 | 2,188.57 | 3,135.9 | 1,947.93 | 1,540.99 | 1,837.74 |
| Net Income Ratio
| 0.116 | 0.103 | 0.125 | 0.124 | 0.141 | 0.161 | 0.1 | 0.247 | 0.231 | 0.267 | 0.263 | 0.257 | 0.28 | 0.304 | 0.307 | 0.237 | 0.263 | 0.363 | 0.339 | 0.239 | 0.278 |
| EPS
| 9.93 | 8.73 | 11.68 | 11.65 | 11.78 | 11.79 | 4.78 | 14.08 | 14.65 | 13.93 | 17.4 | 16.62 | 18.37 | 21.41 | 16.37 | 12.83 | 13.4 | 19.21 | 11.93 | 9.44 | 11.25 |
| EPS Diluted
| 9.93 | 8.73 | 11.68 | 11.65 | 11.78 | 11.78 | 4.78 | 14.08 | 14.65 | 13.92 | 17.24 | 16.62 | 18.37 | 21.37 | 16.37 | 12.82 | 13.4 | 19.21 | 11.93 | 9.44 | 11.25 |
| EBITDA
| 3,567.16 | 2,643.97 | 3,586.5 | 3,937.81 | 3,772.34 | 3,314.96 | 1,508.96 | 3,510.81 | 3,624.75 | 3,443.13 | 4,117.52 | 3,945.81 | 4,277.99 | 4,981.18 | 3,743.86 | 2,993.62 | 3,180.52 | 4,447.13 | 2,851.33 | 2,370.59 | 2,792.23 |
| EBITDA Ratio
| 0.254 | 0.189 | 0.233 | 0.255 | 0.275 | 0.274 | 0.192 | 0.374 | 0.347 | 0.402 | 0.379 | 0.371 | 0.396 | 0.432 | 0.441 | 0.348 | 0.383 | 0.515 | 0.497 | 0.367 | 0.422 |